Clinical Outcomes in Patients Receiving Originator Follitropin Alfa and Follitropin Alfa Biosimilars in Real-world Clinical Practice: A Retrospective Study

Overview

Journal J Hum Reprod Sci

Date 2023 Aug 7

PMID 37547084

Authors

Nayana Hitesh Patel

Niket H Patel

Molina Niket Patel

Harsha K Bhadarka

Kairavi Sunilkumar Vyas

Affiliations

Soon will be listed here.

Abstract

Background: Biosimilar drugs have broadened the treatment options in assisted reproductive technology (ART). Real-world data comparing clinical outcomes of originator follitropin alfa (Gonal-f) with its biosimilars are required to enrich the body of evidence for clinical decision-making on choice of drug.

Aims: To compare the ART outcomes in patients receiving originator follitropin (Gonal-f) and its biosimilars in clinical setting.

Settings And Design: Medical records of 364 infertile women who underwent ART between 2016 and 2020 at Akanksha Hospital and Research Institute, Gujrat, India, were retrospectively analysed.

Materials And Methods: Participants were divided into two cohorts based on treatment (Gonal-f cohort; = 174 and biosimilar cohort; = 190), each cohort further subdivided into group A (age <35 years) and group B (age ≥35 years). Fresh or frozen embryo transfer was performed as per the standard procedures of the clinic. Pregnancy rates and live birth rate (LBR) were the primary main outcome measures in this study.

Statistical Analysis Used: Descriptive statistics and Chi-square test were used for analysis.

Results: The number of oocytes retrieved from Gonal-f and biosimilar cohorts were comparable (13.3 vs. 14.4). Compared to biosimilars, Gonal-f treatment resulted in higher yield of cleavage stage and blastocyst stage embryos, and the proportion of women with good quality embryos was higher in the Gonal-f cohort than the biosimilar cohort (83.3% vs. 69.5%). Patients receiving Gonal-f reported higher pregnancy rates (59.2% vs. 39.7%) and LBR (43% vs. 17.7%) compared to those receiving biosimilars.

Conclusions: Gonal-f (originator follitropin) treatment could result in higher pregnancy rates and LBR in comparison to biosimilars in real-world setting.

Citing Articles

Clinical outcomes of three follitropin alfa preparations for ovarian stimulation using an oral micronized progesterone-primed protocol in an oocyte donation program.

Cruz M, Howles C Front Endocrinol (Lausanne). 2024; 15:1451668.

PMID: 39398338 PMC: 11467753. DOI: 10.3389/fendo.2024.1451668.

Erratum: Clinical Outcomes in Patients Receiving Originator Follitropin Alfa and Follitropin Alfa Biosimilars in Real-world Clinical Practice: A Retrospective Study.

J Hum Reprod Sci. 2023; 16(3):263-265.

PMID: 38045504 PMC: 10688276. DOI: 10.4103/0974-1208.386502.

References

Mastrangeli R, Satwekar A, Cutillo F, Ciampolillo C, Palinsky W, Longobardi S . In-vivo biological activity and glycosylation analysis of a biosimilar recombinant human follicle-stimulating hormone product (Bemfola) compared with its reference medicinal product (GONAL-f). PLoS One. 2017; 12(9):e0184139. PMC: 5589168. DOI: 10.1371/journal.pone.0184139. View

Bergandi L, Canosa S, Carosso A, Paschero C, Gennarelli G, Silvagno F . Human Recombinant FSH and Its Biosimilars: Clinical Efficacy, Safety, and Cost-Effectiveness in Controlled Ovarian Stimulation for In Vitro Fertilization. Pharmaceuticals (Basel). 2020; 13(7). PMC: 7407829. DOI: 10.3390/ph13070136. View

Vignarajan C, Singh N, Vanamail P . The Effect of Follicle-Stimulating Hormone Administration on the Day of Human Chorionic Gonadotropin Trigger on Assisted Reproductive Technique Outcomes in Patients Undergoing Fertilization-Embryo Transfer: A Retrospective Cohort Study. J Hum Reprod Sci. 2020; 13(3):196-200. PMC: 7727880. DOI: 10.4103/jhrs.JHRS_137_19. View

Chua S, Mol B, Longobardi S, Orvieto R, Venetis C, Lispi M . Biosimilar recombinant follitropin alfa preparations versus the reference product (Gonal-F®) in couples undergoing assisted reproductive technology treatment: a systematic review and meta-analysis. Reprod Biol Endocrinol. 2021; 19(1):51. PMC: 8017804. DOI: 10.1186/s12958-021-00727-y. View

Mignini Renzini M, Brigante C, Coticchio G, Dal Canto M, Caliari I, Comi R . Retrospective analysis of treatments with recombinant FSH and recombinant LH versus human menopausal gonadotropin in women with reduced ovarian reserve. J Assist Reprod Genet. 2017; 34(12):1645-1651. PMC: 5714826. DOI: 10.1007/s10815-017-1034-z. View

Grynberg M, Murphy C, Dore C, Fresneau L, Paillet S, Petrica N . A cost-effectiveness analysis comparing the originator follitropin alfa to its biosimilars in patients undergoing a medically assisted reproduction program from a French perspective. J Med Econ. 2018; :1-15. DOI: 10.1080/13696998.2018.1551226. View

Van den Haute L, Drakopoulos P, Verheyen G, De Vos M, Tournaye H, Blockeel C . Follitropin alpha versus beta in a first GnRH antagonist ICSI cycle: a retrospective cohort study. Reprod Biomed Online. 2021; 43(4):655-662. DOI: 10.1016/j.rbmo.2021.06.014. View

Braam S, de Bruin J, Buisman E, Brandes M, Nelen W, Smeenk J . Treatment strategies and cumulative live birth rates in WHO-II ovulation disorders. Eur J Obstet Gynecol Reprod Biol. 2018; 225:84-89. DOI: 10.1016/j.ejogrb.2018.04.006. View

Strowitzki T, Kuczynski W, Mueller A, Bias P . Randomized, active-controlled, comparative phase 3 efficacy and safety equivalence trial of Ovaleap® (recombinant human follicle-stimulating hormone) in infertile women using assisted reproduction technology (ART). Reprod Biol Endocrinol. 2016; 14:1. PMC: 4702416. DOI: 10.1186/s12958-015-0135-8. View

10.

Christianson M, Shoham G, Tobler K, Zhao Y, Monseur B, Leong M . Use of various gonadotropin and biosimilar formulations for in vitro fertilization cycles: results of a worldwide Web-based survey. J Assist Reprod Genet. 2017; 34(8):1059-1066. PMC: 5533682. DOI: 10.1007/s10815-017-0952-0. View

11.

Clarke J, van Rumste M, Farquhar C, Johnson N, Mol B, Herbison P . Measuring outcomes in fertility trials: can we rely on clinical pregnancy rates?. Fertil Steril. 2010; 94(5):1647-51. DOI: 10.1016/j.fertnstert.2009.11.018. View

12.

Goldstajn M, Dumancic S, Mikus M . Retrospective analysis of the use of two recombinant follitropin alfa injections in patients undergoing in vitro fertilization treatment with the gonadotropin-releasing hormone antagonist protocol. J Obstet Gynaecol Res. 2020; 47(3):992-1001. DOI: 10.1111/jog.14626. View

13.

Kaida-Yip F, Deshpande K, Saran T, Vyas D . Biosimilars: Review of current applications, obstacles, and their future in medicine. World J Clin Cases. 2018; 6(8):161-166. PMC: 6107532. DOI: 10.12998/wjcc.v6.i8.161. View

14.

Tabata C, Fujiwara T, Sugawa M, Noma M, Onoue H, Kusumi M . Comparison of FSH and hMG on ovarian stimulation outcome with a GnRH antagonist protocol in younger and advanced reproductive age women. Reprod Med Biol. 2015; 14:5-9. PMC: 4300428. DOI: 10.1007/s12522-014-0186-0. View

15.

Mochtar M, Danhof N, Ayeleke R, van der Veen F, van Wely M . Recombinant luteinizing hormone (rLH) and recombinant follicle stimulating hormone (rFSH) for ovarian stimulation in IVF/ICSI cycles. Cochrane Database Syst Rev. 2017; 5:CD005070. PMC: 6481753. DOI: 10.1002/14651858.CD005070.pub3. View

16.

Bordewijk E, Mol F, van der Veen F, van Wely M . Required amount of rFSH, HP-hMG and HP-FSH to reach a live birth: a systematic review and meta-analysis. Hum Reprod Open. 2019; 2019(3):hoz008. PMC: 6561325. DOI: 10.1093/hropen/hoz008. View

17.

Revelli A, Gennarelli G, Sestero M, Canosa S, Carosso A, Salvagno F . A prospective randomized trial comparing corifollitropin-α late-start (day 4) versus standard administration (day 2) in expected poor, normal, and high responders undergoing controlled ovarian stimulation for IVF. J Assist Reprod Genet. 2020; 37(5):1163-1170. PMC: 7244653. DOI: 10.1007/s10815-020-01742-5. View

18.

Gizzo S, Ferrando M, Lispi M, Ripellino C, Cataldo N, Buhler K . A cost-effectiveness modeling evaluation comparing a biosimilar follitropin alfa preparation with its reference product for live birth outcome in Germany, Italy and Spain. J Med Econ. 2018; 21(11):1096-1101. DOI: 10.1080/13696998.2018.1511567. View

19.

Schwarze J, Venetis C, Iniesta S, Falla E, Lukyanov V, de Agustin Calvo E . Originator recombinant human follitropin alfa versus recombinant human follitropin alfa biosimilars in Spain: A cost-effectiveness analysis of assisted reproductive technology related to fresh embryo transfers. Best Pract Res Clin Obstet Gynaecol. 2022; 85(Pt B):203-216. DOI: 10.1016/j.bpobgyn.2022.01.011. View

20.

Gizzo S, Garcia-Velasco J, Heiman F, Ripellino C, Buhler K . A cost-effectiveness evaluation comparing originator follitropin alfa to the biosimilar for the treatment of infertility. Int J Womens Health. 2016; 8:683-689. PMC: 5153281. DOI: 10.2147/IJWH.S118687. View